Pritzker Levine LLP, Robbins Geller Rudman & Dowd LLP, Sharp Law, LLP,...

Pritzker Levine LLP, Robbins Geller Rudman & Dowd LLP, Sharp Law, LLP, Burns Charest LLP and Keller Rohrback L.L.P., Announce a $345 Million Class Action Settlement with Defendant Pfizer Inc. for Purchasers of EpiPen, EpiPen Jr. and/or their Authorized Generics



SHARE THIS ARTICLE

KANSAS CITY, Kan., Aug. 4, 2021 /PRNewswire-HISPANIC PR WIRE/ —

$345 Million Dollar Epinephrine Auto-Injector (“EpiPen®”) Class Action
Settlement with Pfizer

In re EPIPEN (EPINEPHRINE INJECTION, USP) MARKETING,
SALES PRACTICES AND ANTITRUST LITIGATION
Case No. 2:17-md-02785-DDC-TJJ, MDL 2785 (District of Kansas)

To register to receive compensation, visit www.EpiPenClassAction.com/fileclaim

Who Is Eligible?

People or entities that paid for some or all of the purchase price of a branded or authorized generic EpiPen® or EpiPen Jr® for the purpose of consumption, and not resale.  This includes:

  • Yourself
  • Family members
  • Plan participants or employees

This lawsuit asserts that Defendants violated certain state antitrust and federal racketeering laws, harming competition, and causing class members to overpay for EpiPen products. Defendants deny these allegations.

PLEASE NOTE:  This is NOT a recall, safety, or other similar notice. No one is claiming that EpiPen products are unsafe or ineffective. 

If you purchased or paid for an EpiPen® or EpiPen Jr® at any time between August 24, 2011 and November 1, 2020, your rights will be affected by this class action settlement with the Pfizer Defendants (Pfizer Inc., King Pharmaceuticals LLC and Meridian Medical Technologies, Inc.). Plaintiffs are still litigating against other Defendants with a trial scheduled for January 24, 2022.

If you fall into one of these categories you are a Class Member (unless you are excluded by the class definition, available on the settlement website) and you may:

  1. Share in the distribution of settlement funds OR
  2. Object. Any objection to the Settlement, the Plan of Allocation, or the fee and expense application must be filed with the Court and sent to and received by counsel for the parties no later than September 24, 2021:

Clerk of the Court
United States District Court, District of Kansas
500 State Avenue
Kansas City, KS  66101

Rex A. Sharp
SHARP LAW, LLP
4820 West 75th Street
Prairie Village, KS  66208

Raj S. Gandesha
WHITE & CASE LLP
1221 Avenue of the Americas
New York, NY 10020

If you are a Class Member and did not timely request exclusion prior to January 15, 2020, you will be bound by any judgment in the Action. You may appear in court through an attorney at your expense. The Court will hold a hearing on October 27, 2021, at 9:00 a.m. Central Time to consider whether to approve the Settlement, attorneys’ fees, expenses and service awards.

To share in the distribution of the Net Settlement Fund, Class Members must submit a Proof of Claim through the settlement website or by mail. If submitted through the settlement website, the Proof of Claim must be received no later than November 12, 2021. If submitted by mail, the Proof of Claim must be postmarked no later than November 12, 2021. Unless the deadline is extended, failure to submit your timely Proof of Claim will preclude you from receiving any payment from the Settlement.

For more information about how to participate in this proposed class action settlement with the Pfizer Inc. defendants only, please visit www.EpiPenClassAction.com, call 1–877-221-7632, or write to:

EpiPen Settlement
c/o A.B. Data, Ltd.
P.O. Box 173113
Milwaukee, WI 53217

August 4, 2021

SOURCE Robbins Geller Rudman & Dowd LLP

Pritzker Levine LLP, Robbins Geller Rudman & Dowd LLP, Sharp Law, LLP, Burns Charest LLP and Keller Rohrback L.L.P., Announce a $345 Million Class Action Settlement with Defendant Pfizer Inc. for Purchasers of EpiPen, EpiPen Jr. and/or their Authorized Generics